A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia

Elizabeth A. Griffiths*, William E. Brady, Wei Tan, Carlos E. Vigil, James E. Thompson, Laurie A. Ford, Noelle M. Dickey, Heather L. Bashaw, Jill Sperrazza, Meir Wetzler, Eunice S. Wang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) remains a therapeutic challenge. Cytarabine arabinoside (AraC) forms the backbone of most regimens, with complete responses (CR) ranging from 17 to 20%. Lenalidomide (Len) is approved by the FDA for multiple myeloma and myelodysplasia and has demonstrated activity in AML. We developed a phase I study to evaluate the safety and tolerability of Len in combination with intermediate dose AraC (1.5 g/m2/day given on days 1-5) in adults with r/r AML. The maximally tolerated dose for this combination was 10 mg daily on days 6-26 of a 28 day cycle. Dose de-escalation from 25 mg was required due to rash, liver function abnormalities, and hypokalemia. Of 32 evaluable patients, five achieved CR (16%), 5CRi (16%) and 3 had hematological improvements for an overall response rate of 41% (13/32). Median overall survival (95% confidence interval) for patients treated on study was 5.8 (2.5-10.6) months and disease free survival was 3.4 (2.3-6.2) months. This single institute phase I trial of Len and intermediate dose AraC was associated with marked skin and other toxicities. At the dose and schedule tested, this combination did not appear to result in improved CR over single agent AraC for r/r AML.

Original languageEnglish (US)
Pages (from-to)44-48
Number of pages5
JournalLeukemia Research
Volume43
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Clinical trial
  • Cytarabine
  • Lenalidomide
  • Phase I
  • Relapse/refractory AML

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this